Re: Why now?
in response to
by
posted on
Jan 12, 2021 08:27AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Almost pooped my drawers when I fired up the screens this morning. My account balance had a mysterious drop. Go figure TD revalued the Zen shares from .85 down to .35. Phew. I called and asked them to remove from my portfolio or give a value of 0.00. They could not do that and the only option was to transfer to a inactive account. So I told them open another account and I would send RVX over to keep Zen company. Hahahaha
CCD